SCHEMBL4476092

SCHEMBL4476092

NC(N)=Nc1ccc([N+](=O)[O-])cc1Cl

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.57
HSD17B10 Q99714 1/20 0.55
PLAU P00749 2/20 0.54
HGFAC Q04756 1/20 0.53
ADRA2A P08913 2/20 0.47
ADRA2B P18089 2/20 0.47
ADRA2C P18825 2/20 0.47
MEN1 O00255 3/20 0.47
NPC1 O15118 1/20 0.47
ALDH1A1 P00352 3/20 0.47
MAPT P10636 2/20 0.47
CYP1A2 P05177 1/20 0.47
POLB P06746 1/20 0.47
CYP3A4 P08684 1/20 0.47
PRMT1 Q99873 1/20 0.47
VCAM1 P19320 1/20 0.46
HTR3E A5X5Y0 2/20 0.46
HTR3B O95264 2/20 0.46
HTR3A P46098 2/20 0.46
HTR3D Q70Z44 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11878505 0.80 PLAU (0.54) KMT2APLAUHGFACADRA2AADRA2B
SCHEMBL11880304 0.80 PLAU (0.54) KMT2APLAUHGFACADRA2AADRA2B
SCHEMBL11876448 0.80 GRIN2D (0.66) KMT2APLAUADRA2AADRA2BADRA2C
SCHEMBL10788312 0.79 HSD17B10 (0.62) KMT2AHSD17B10MEN1NPC1ALDH1A1
SCHEMBL1513945 0.78 HSD17B10 (0.56) KMT2AHSD17B10MEN1NPC1ALDH1A1
SCHEMBL29471399 0.78 HSD17B10 (0.56) KMT2AHSD17B10MEN1NPC1ALDH1A1
Nitric Acid SCHEMBL3858362 0.78 GRIN2D (0.63) KMT2APLAUADRA2AADRA2BADRA2C
SCHEMBL11878490 0.78 PLAU (0.51) KMT2APLAUADRA2AADRA2BADRA2C
SCHEMBL11879323 0.77 ALDH1A1 (0.55) KMT2AHSD17B10PLAUHGFACADRA2A
SCHEMBL9638395 0.77 HSD17B10 (0.60) KMT2AHSD17B10MEN1NPC1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7501415-B2 Selective inhibitors of ERK protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED (US) 2009-03-10 US disclosed
EP-1833820-A1 SELECTIVE INHIBITORS OF ERK PROTEIN KINASE AND USES THEROF Vertex Pharmaceuticals Incorporated (US) 2007-09-19 EP disclosed
US-20060160807-A1 Selective inhibitors of ERK protein kinase and uses thereof VERTEX PHARMACEUTICALS INCORPORATED 2006-07-20 US disclosed
WO-2006071644-A1 SELECTIVE INHIBITORS OF ERK PROTEIN KINASES AND USES THEROF VERTEX PHARMACEUTICALS INCORPORATED (US) 2006-07-06 WO disclosed
US-3976643-A FROM AN ANILINE AND CYANAMIDE WILLIAM H. RORER, INC. (US) 1976-08-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060160807-A1 Selective inhibitors of ERK protein kinase and uses thereof MAP3K20, MAP4K2, MAP4K1 KMT2A 3000/4885HSD17B10 2581/4885PLAU 2632/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.